Sertraline Hydrochloride Tablet
Product Images NDC 68071-3951

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sertraline Hydrochloride (NDC 68071-3951). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3951 3)

Label for SERTRALINE HYDROCHLORIDE 25 mg tablets by NuCare Pharmaceuticals, Inc. The label indicates a package of 30 tablets, film-coated with each tablet containing 28 mg sertraline hydrochloride equivalent to 25 mg sertraline USP. Tablets are described as green capsule-shaped with debossed 'T' and '25'. The label includes directions for use, manufacturer and packaging information, storage conditions, and safety warnings. NDC 68071-3951-3 is visible along with lot and expiration placeholder data.*

FDA Label Image

Image Description (Struct)

Chemical structure of sertraline hydrochloride, showing the molecular arrangement including chlorinated aromatic rings and a methylated amine group, as well as association with hydrochloride (HCl).*

FDA Label Image

Table 3 (Table 3)

Table listing common adverse reactions in pooled placebo-controlled trials comparing sertraline hydrochloride and placebo in adults with MDD, OCD, PD, PTSD, SAD, and PMDD. The table shows percentages of patients experiencing various side effects by system disorder categories for sertraline hydrochloride (N=3066) and placebo (N=2293), highlighting reactions such as nausea, insomnia, and fatigue.*

FDA Label Image

Table1 (Table1)

A data table titled 'Recommended Daily Dosage of sertraline hydrochloride in Patients with MDD, OCD, PD, PTSD, and SAD' presenting starting doses and therapeutic ranges for adults and pediatric patients. Starting doses range from 25 mg to 50 mg, with a therapeutic range of 50-200 mg for most indications.*

FDA Label Image

Table2 (Table2)

A data table titled 'Risk Differences of the Number of Cases of Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric and Adult Patients.' The table shows age ranges with corresponding differences in the number of patients experiencing suicidal thoughts or behaviors per 1000 patients treated, comparing drug versus placebo. It lists increases compared to placebo in patients under 18 and 18-24, and decreases in age groups 25-64 and 65 or older.*

FDA Label Image

Image Description (Table4)

A data table summarizing the most common sexual adverse reactions occurring at rates of 2% or more and at least twice as frequent as placebo in adults treated with sertraline hydrochloride compared to placebo. The table divides results by men and women, showing specific adverse reactions such as ejaculation failure, decreased libido, erectile dysfunction, and male sexual dysfunction with associated percentages for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.